Literature DB >> 7319919

New rifamycins modified at positions 3 and 4. Synthesis, structure and biological evaluation.

L Marsili, C R Pasqualucci, A Vigevani, B Gioia, G Schioppacassi, G Oronzo.   

Abstract

A number of semisynthetic rifamycin derivatives modified at positions 3 and/or 4, belonging to general structures 3, 5, and 6 (see Scheme 1), have been prepared. The synthesis, structure and antimicrobial evaluation of the new compounds are described. All the derivatives have "in vitro" antibacterial activities well comparable with that of rifampicin.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7319919     DOI： 10.7164/antibiotics.34.1033

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  8 in total

1.  Strong in vitro activities of two new rifabutin analogs against multidrug-resistant Mycobacterium tuberculosis.

Authors:  Ana-Belén García; Juan J Palacios; María-Jesús Ruiz; José Barluenga; Fernando Aznar; María-Paz Cabal; José María García; Natalia Díaz
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

2.  Prediction of drug resistance profile of multidrug-resistant Mycobacterium tuberculosis (MDR-MTB) isolates from newly diagnosed case by whole genome sequencing (WGS): a study from a high tuberculosis burden country.

Authors:  Wenwen Sun; Xuwei Gui; Zheyuan Wu; Yangyi Zhang; Liping Yan
Journal:  BMC Infect Dis       Date:  2022-05-27       Impact factor: 3.667

3.  Pharmacokinetics of rifabutin.

Authors:  M H Skinner; M Hsieh; J Torseth; D Pauloin; G Bhatia; S Harkonen; T C Merigan; T F Blaschke
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

4.  Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis.

Authors:  F B Jamieson; J L Guthrie; A Neemuchwala; O Lastovetska; R G Melano; C Mehaffy
Journal:  J Clin Microbiol       Date:  2014-04-16       Impact factor: 5.948

Review 5.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

6.  Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates.

Authors:  Wei Jing; Yu Pang; Zhaojing Zong; Jing Wang; Ru Guo; Fengmin Huo; Guanglu Jiang; Yifeng Ma; Hairong Huang; Naihui Chu
Journal:  Front Microbiol       Date:  2017-09-14       Impact factor: 5.640

7.  Drug Resistance Characteristics of Mycobacterium tuberculosis Isolates From Patients With Tuberculosis to 12 Antituberculous Drugs in China.

Authors:  Xiaocui Wu; Jinghui Yang; Guangkun Tan; Haican Liu; Yin Liu; Yinjuan Guo; Rongliang Gao; Baoshan Wan; Fangyou Yu
Journal:  Front Cell Infect Microbiol       Date:  2019-11-05       Impact factor: 5.293

8.  A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens.

Authors:  James Peek; Jiayi Xu; Han Wang; Shraddha Suryavanshi; Matthew Zimmerman; Riccardo Russo; Steven Park; David S Perlin; Sean F Brady
Journal:  ACS Infect Dis       Date:  2020-08-25       Impact factor: 5.084
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.